Valuation: PREDILIFE

Market Cap 41.44L 0 47.27L 38.5L 35.35L 66.57L 46Cr 67.63L 4.59Cr 1.79Cr 22Cr 1.77Cr 1.74Cr 77Cr P/E 2024
-3.18x
P/E 2025 -3.01x
Enterprise Value 89.21L 0 1.02Cr 82.89L 76.12L 1.43Cr 98Cr 1.46Cr 9.87Cr 3.86Cr 48Cr 3.82Cr 3.74Cr 165.98Cr EV / Sales 2024
34.5x
EV / Sales 2025 19.3x
Free-Float
48.75%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 56 01/01/2004
Chief Tech/Sci/R&D Officer - 01/01/2007
General Counsel - 01/01/2016
Director TitleAgeSince
Chairman 56 01/01/2004
Director/Board Member 46 01/01/2018
Director/Board Member 58 01/01/2018
Change 5-day change 1-year change 3-year change Capi.($)
+0.95%-.--%+116.94%+10.40% 2TCr
-2.55%+2.45%+151.89%+102.97% 475.01Cr
-2.79%+2.43%+112.90%+171.66% 361.38Cr
-5.66%+31.55%+107.63%-32.59% 244.68Cr
+2.01%+3.82%-26.08%-35.34% 208.33Cr
-1.97%+30.59%+196.31%+255.41% 199.1Cr
0.00%+9.06%+198.32%-43.20% 104.73Cr
-1.10%-2.71%-13.50%+25.12% 84Cr
-0.14%+1.86%-36.72%-14.16% 49Cr
Average -1.25%+8.34%+89.74%+48.92% 414.33Cr
Weighted average by Cap. -0.48%+5.43%+113.96%+44.02%

Financials

2024 2025
Net sales 5L 0 6L 5L 4L 8L 5.43Cr 8L 54.59L 21.33L 2.66Cr 21.12L 20.66L 9.18Cr 8L 0 10L 8L 7L 13.43L 9.21Cr 13.64L 92.51L 36.15L 4.5Cr 35.79L 35.02L 16Cr
Net income -42.65L -0 -48.65L -39.63L -36.39L -68.52L -47Cr -69.61L -4.72Cr -1.84Cr -23Cr -1.83Cr -1.79Cr -79Cr -39.34L -0 -44.88L -36.56L -33.57L -63.21L -43Cr -64.22L -4.35Cr -1.7Cr -21Cr -1.68Cr -1.65Cr -73Cr
Net Debt 35.38L 0 40.36L 32.88L 30.19L 56.85L 39Cr 57.75L 3.92Cr 1.53Cr 19Cr 1.52Cr 1.48Cr 66Cr 47.78L 0 54.5L 44.39L 40.76L 76.76L 53Cr 77.98L 5.29Cr 2.07Cr 26Cr 2.05Cr 2Cr 89Cr
Logo PREDILIFE
PREDILIFE specializes in the development of predictive tests, particularly in the field of oncology. The company has MammoRisk®, a breast cancer predictive test that uses a first mammogram and a few questions to obtain a first risk assessment. A genetic test then makes it possible to estimate the risk of breast cancer more accurately. The technology used by MammoRisk® makes it possible to evaluate, from a database of individuals monitored over time, the risks of an individual compared to the future of his « closest » neighbours thanks to a database of over 1,000,000 American women, and over 300,000 French women. PREDILIFE also develops multi-pathology tests to screen for colon, prostate and lung cancer, melanoma and cardiovascular risks.
Employees
-